Cargando…
Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay
Botulinum neurotoxin serotype A (BoNT/A), a potent therapeutic used to treat various disorders, inhibits vesicular neurotransmitter exocytosis by cleaving SNAP25. Development of cell-based potency assays (CBPAs) to assess the biological function of BoNT/A have been challenging because of its potency...
Autores principales: | Fernández-Salas, Ester, Wang, Joanne, Molina, Yanira, Nelson, Jeremy B., Jacky, Birgitte P. S., Aoki, K. Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504020/ https://www.ncbi.nlm.nih.gov/pubmed/23185348 http://dx.doi.org/10.1371/journal.pone.0049516 |
Ejemplares similares
-
Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A)
por: Jacky, Birgitte P. S., et al.
Publicado: (2013) -
Content/Potency Assessment of Botulinum Neurotoxin Type-A by Validated Liquid Chromatography Methods and Bioassays
por: Xavier, Bruna, et al.
Publicado: (2019) -
Emerging Opportunities for Serotypes of Botulinum Neurotoxins
por: Peng Chen, Zhongxing, et al.
Publicado: (2012) -
Botulinum Neurotoxins Serotypes A and B induce paralysis of mouse striated and smooth muscles with different potencies
por: Maignel‐Ludop, Jacquie, et al.
Publicado: (2017) -
Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay
por: James, Nicholas G., et al.
Publicado: (2021)